Interferon alpha-2b biosimilar - Nanogen Biopharmaceutical

Drug Profile

Interferon alpha-2b biosimilar - Nanogen Biopharmaceutical

Alternative Names: Recombinant human interferon alfa 2b - Nanogen

Latest Information Update: 14 Mar 2014

Price : $50

At a glance

  • Originator Nanogen Biopharmaceutical Co
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer; Condylomata acuminata; Hepatitis B; Hepatitis C

Most Recent Events

  • 14 Mar 2014 Early research in Hepatitis C in Vietnam (Parenteral)
  • 14 Mar 2014 Early research in Hepatitis B in Vietnam (Parenteral)
  • 14 Mar 2014 Early research in Condylomata acuminata in Vietnam (Intralesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top